Last quarter (Q4 2022), Recce Pharmaceuticals Ltd.'s total revenue was $―, a decrease of ― from the same quarter last year. In Q4, Recce Pharmaceuticals Ltd.'s net income was $―. See Recce Pharmaceuticals Ltd.’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Jun 22	Jun 21	Jun 20	Jun 19	Jun 18
Total Revenue	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Cost of Revenue	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Gross Profit	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Operating Expense	$ ―	$ 12.60M	$ 15.20M	$ 5.26M	$ 3.31M	$ 2.82M
Operating Income	$ ―	$ -12.60M	$ -15.20M	$ -5.26M	$ -3.31M	$ -2.82M
Net Non Operating Interest Income Expense	$ ―	$ 79.07K	$ 93.62K	$ -30.64K	$ -49.70K	$ -42.29K
Other Income Expense	$ ―	$ 1.53M	$ 1.59M	$ 974.23K	$ 571.34K	$ 1.19M
Pretax Income	$ ―	$ -10.99M	$ -13.51M	$ -4.32M	$ -2.79M	$ -1.67M
Tax Provision	$ ―	$ 0.00	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Earnings From Equity Interest Net Of Tax	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Net Income Common Stockholders	$ ―	$ -10.99M	$ -13.51M	$ -4.32M	$ -2.79M	$ -1.67M
Basic EPS	$ ―	$ -0.06	$ -0.09	$ -0.03	$ -0.03	$ ―
Diluted EPS	$ ―	$ -0.06	$ -0.09	$ -0.03	$ -0.03	$ ―
Basic Average Shares	$ ―	$ 174.13M	$ 155.40M	$ 127.21M	$ 94.47M	$ ―
Diluted Average Shares	$ ―	$ 174.13M	$ 155.40M	$ 127.21M	$ 94.47M	$ ―
Dividend Per Share	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Total Operating Income As Reported	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Reported Normalized Basic E P S	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Reported Normalized Diluted E P S	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Rent Expense Supplemental	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Total Expenses	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Net Income From Continuing And Discontinued Operation	$ ―	$ -10.99M	$ -13.51M	$ -4.32M	$ -2.79M	$ -1.67M
Normalized Income	$ ―	$ -10.99M	$ -13.51M	$ -4.32M	$ -2.79M	$ -1.67M
Interest Expense	$ ―	$ 2.42K	$ 2.11K	$ 45.85K	$ 56.69K	$ 54.31K
EBIT	$ ―	$ -10.98M	$ -13.51M	$ -4.27M	$ -2.73M	$ -1.62M
EBITDA	$ ―	$ -10.80M	$ -13.22M	$ -4.07M	$ -2.68M	$ -1.57M

Currency in USD

Recce Pharmaceuticals Ltd. Earnings and Revenue History

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing